Dimethyl fumarate and its esters: A drug with broad clinical utility?

60Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.

Abstract

Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.

Cite

CITATION STYLE

APA

Kourakis, S., Timpani, C. A., de Haan, J. B., Gueven, N., Fischer, D., & Rybalka, E. (2020, October 1). Dimethyl fumarate and its esters: A drug with broad clinical utility? Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph13100306

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free